Boehringer's lung drug gets a boost from European regulators

Boehringer Ingelheim persuaded EU officials to put its lung-disease drug nintedanib on its development fast track, speeding its path to market as a treatment for idiopathic pulmonary fibrosis (IPF). Boehringer is in a race with InterMune, whose rival drug pirfenidone is already sold in Europe, but so far has struggled to catch on. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.